Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is the most common form of irreversible blindness in developed countries. Variants in the factor H gene (CFH, also known as HF1), which encodes a major inhibitor of the alternative complement pathway, are associated with the risk for developing AMD. Here we test the hypothesis that variation in genes encoding other regulatory proteins of the same pathway is associated with AMD. We screened factor B (BF) and complement component 2 (C2) genes, located in the major histocompatibility complex class III region, for genetic variation in two independent cohorts comprising approximately 900 individuals with AMD and approximately 400 matched controls. Haplotype analyses identify a statistically significant common risk haplotype (H1) and two protective haplotypes. The L9H variant of BF and the E318D variant of C2 (H10), as well as a variant in intron 10 of C2 and the R32Q variant of BF (H7), confer a significantly reduced risk of AMD (odds ratio = 0.45 and 0.36, respectively). Combined analysis of the C2 and BF haplotypes and CFH variants shows that variation in the two loci can predict the clinical outcome in 74% of the affected individuals and 56% of the controls. These data expand and refine our understanding of the genetic risk for AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This analysis resulted in the identification of the previously well documented independently associated variants near CFH and C2/CFB8,10,31,32 and of additional independent signals near C3, CETP, LIPC, FRK/COL10A1, IER3/DDR1, RAD51B (Supplementary Table 6).”
From Seven new loci associated with age-related macular degeneration (2013) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genes in the complement pathway4–11 and a region of chromosome 10 12,13 have now been implicated as the major genetic contributors to disease.”
From Seven new loci associated with age-related macular degeneration (2013) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“These include complement 2 (C2) and/or complement factor B (CFB) (56), complement 3 (C3) (170), and complement factor I (CFI) (44).”
From Unraveling a Multifactorial Late-Onset Disease: From Genetic Susceptibility to Disease Mechanisms for Age-Related Macular Degeneration (2009) · cites this paper as [56]
In the citing paper
“studies have demonstrated that at least one of the two variants associated with AMD—R32Q BF—leads to an impairment in the complement activating function of BF (Gold et al., 2006).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Gold et al., 2006
In the citing paper
“the L9H BF/E318D C2 and R32Q BF/intronic variants of C2 have been shown to be protective for AMD (odds ratio (OR) = 0.45 and 0.36, respectively) by Gold et al.”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Gold et al., 2006
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“Overall type I error rates (α) were retrospectively calculated using a previously described metho”
MethodComplement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Self-citationBird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265
Self-citationDrusen proteome analysis: an approach to the etiology of age-related macular degeneration
Crabb, J. W., Miyagi, M., Gu, X., Shadrach, K., West, K. A., Sakaguchi, H., Kamei, M., Hasan, A., Yan, L., Rayborn, M. E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222551899 · Cited by 1,208
A Fine-Scale Map of Recombination Rates and Hotspots Across the Human Genome
Myers, S., Bottolo, L., Freeman, C., McVean, G., & Donnelly, P. (2005) · Science · doi:10.1126/science.1117196 · Cited by 1,134 · cited 1×
“Fourth, estimated recombination rates from HapMap data indicate regions of high recombination on both sides of the C2/BF locu”
BackgroundA role for local inflammation in the formation of drusen in the aging eye
Anderson, D. H., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01624-0 · Cited by 1,087
Self-citation
Cited by
Items 701–800 of 1,000
Woo, H. J., Yu, C., Kumar, K., Gold, B., & Reifman, J. (2016) · BMC Genomics · doi:10.1186/s12864-016-2871-3 · Cited by 14
Self-citationWhole exome sequencing of extreme age-related macular degeneration phenotypes.
Sardell, R. J., Bailey, J. N. C., Courtenay, M. D., Whitehead, P. L., Laux, R. A., Adams, L. D., Fortun, J. A., Brantley, M. A., Kovach, J. L., Schwartz, S. G., et al. (2016) · PubMed Central · Cited by 17
AMD Genetics: Methods and Analyses for Association, Progression, and Prediction
Yan, Q., Ding, Y., Weeks, D. E., & Chen, W. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-66014-7_7 · Cited by 14
Kaiser, P. K., Karpecki, P. M., Regillo, C. D., Baumal, C. R., Ryan, E. H., Ip, M. S., Modi, Y. S., Yeu, E., Nijm, L. M., Farid, M., et al. (2023) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2023-001395 · Cited by 14
AICAR suppresses TNF-α-induced complement factor B in RPE cells
Chung, E. J., Efstathiou, N. E., Konstantinou, E. K., Maidana, D. E., Miller, J. W., YOUNG, L. H. Y., & Vavvas, D. G. (2017) · Scientific Reports · doi:10.1038/s41598-017-17744-w · Cited by 14
Chrzanowska, M., Modrzejewska, A., & Modrzejewska, M. (2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.11.19 · Cited by 17
Gorin, M. B., & daSilva, M. J. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107894 · Cited by 14
de Almeida, L. N. F., Melilo-Carolino, R., Veloso, C. E. D. R., Pereira, P. A., Bastos‐Rodrigues, L., Sarubi, H., de Miranda, D. M., Soubrane, G., Marco, L. A. D., & Nehemy, M. B. (2013) · Ophthalmic Research · doi:10.1159/000350549 · Cited by 15
Complement Deposits on Ocular Tissues Adjacent to Sites of Inflammation
Montalvo, V., Chan, C., Gery, I., Campos, M. M., Wawrousek, E. F., Bush, R. A., & Lambris, J. D. (2007) · Current Eye Research · doi:10.1080/02713680701656343 · Cited by 14
Carboxyethylpyrrole Adducts, Age-related Macular Degeneration and Neovascularization
Renganathan, K., Ebrahem, Q., Vasanji, A., Gu, X., Lu, L., Sears, J. E., Salomon, R. G., Anand‐Apte, B., & Crabb, J. W. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_30 · Cited by 17
“Genetic evidence now supports an association between AMD susceptibility and variants in genes encoding complement factor H, factor B, complement component 2 and a heat shock serine protease (Edwards et al., 2005; Gold et al., 2006 ) (Dewan et al., 2006; Hageman et al., 2005; Haines et al., 2005; Jakobsdottir et al., 2…”
BackgroundMartínez‐Barricarte, R., de Jorge, E. G., Montes, T., García‐Layana, A., & de Córdoba, S. R. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03798.x · Cited by 14
Frank, J. W., Ruggiero, E. D., McInnes, R. R., Kramer, M. S., & Gagnon, F. (2006) · Epidemiology · doi:10.1097/01.ede.0000239725.48908.7d · Cited by 18
“This landmark study led to the subsequent recognition that 2 other genes in the alternative complement pathway contribute to the risk as well.(14) In contrast, the only major environmental contributor to age-related macular degeneration that has been identified to date is tobacco and, because most persons with this co…”
BackgroundWang, X., Zhang, Y., & Zhang, M.-N. (2013) · International Journal of Ophthalmology · doi:10.3980/j.issn.2222-3959.2013.06.21 · Cited by 15
Kwong, A. M., Zawistowski, M., Fritsche, L. G., Zhan, X., Bragg‐Gresham, J. L., Branham, K. E. H., Advani, J., Othman, M., Ratnapriya, R., Teslovich, T. M., et al. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad189 · Cited by 14
Hall, J. B., Bailey, J. N. C., Hoffman, J., Pericak‐Vance, M. A., Scott, W. K., Kovach, J. L., Schwartz, S. G., Agarwal, A., Brantley, M. A., Haines, J. L., et al. (2015) · BMC Bioinformatics · doi:10.1186/s12859-015-0760-4 · Cited by 15
“Genetic variants with large effect sizes, several of which are localized to complement system genes, have been repeatedly associated with AMD [5, 6, 8, 12, 20].”
BackgroundMcCarthy, L. C., Newcombe, P. J., Whittaker, J. C., Wurzelmann, J. I., Fries, M. A., Burnham, N. R., Cai, G., Stinnett, S. W., Trivedi, T., & Xu, C. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.021 · Cited by 15
Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization
Jo, D. H., Kim, J. H., Yang, W., Kim, H., Chang, S.-J., Kim, D., Chang, M., Lee, K., Chung, J., & Kim, J. H. (2017) · Oncotarget · doi:10.18632/oncotarget.17221 · Cited by 13
Genetics of Age-related Macular Degeneration
Edwards, A. O. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_24 · Cited by 14
The Landscape of Vascular Endothelial Growth Factor Inhibition in Retinal Diseases
Lin, J. B., & Apte, R. S. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.1.47 · Cited by 13
“Complement inhibition has long been an attractive therapeutic avenue in the treatment of AMD, spurred by foundational pathologic, 31,32 genetic, 33–41 and other preclinical studies demonstrating that complement inhibition reduces CNV in animal models.”
The role of autophagy in age‐related macular degeneration
Kivinen, N. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13753 · Cited by 14
“Several studies have revealed that over 70% of AMD cases are associated with polymorphisms in complement 9 Acta Ophthalmologica 2018 factor H (CFH), complement factor B andcomplement component 2 (C2)genes (Gold et al. 2006; Fritsche et al. 2013).”
BackgroundEfstathiou, N. E., Moustafa, G. A., Maidana, D. E., Konstantinou, E. K., Notomi, S., Barbisan, P. R. T., Georgakopoulos, C. D., Miller, J. W., & Vavvas, D. G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244307 · Cited by 12
“Other studies uncovered the association of additional complement system genes with AMD including CFB/C2 [17, 18], CFI [19, 20], CFD [21] and C3 [22, 23].”
BackgroundNauser, C. L., & Sacks, S. H. (2022) · Immunological Reviews · doi:10.1111/imr.13144 · Cited by 13
Genetic Control of Complement Activation in Humans and Age Related Macular Degeneration
Hecker, L. A., & Edwards, A. O. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-5635-4_4 · Cited by 13
“Indeed, in this locus the common haplotype is the AMD risk haplotype ( Gold et al. 2006 ).”
BackgroundGenetic Basis of Inherited Macular Dystrophies and Implications for Stem Cell Therapy
Mellough, C., STEEL, D. H., & Lako, M. (2009) · Stem Cells · doi:10.1002/stem.159 · Cited by 14
Rojas‐Fernandez, C. H., & Tyber, K. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016680643 · Cited by 12
“There are additional polymorphisms (eg, complement factor B [CFB] and C2 genes), and collectively, polymorphisms in CFH, CFB, and C2 genes may explain almost 75% of AMD cases.(15) CFH is a major inhibitor in the complement pathway, which is synthesized in the macula and is present in drusen.”
BackgroundDang, Y., Shen, Y., Xu, X., Wang, S., Meng, X.-Z., Zhang, M., Lv, L., Wang, R., & Li, J. (2018) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2018.01.030 · Cited by 12
Linetsky, M. D., Bondelid, K. S., Losovskiy, S., Gabyak, V., Rullo, M. J., Stiadle, T. I., Munjapara, V., Saxena, P., Ma, D., Cheng, Y.-S., et al. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00028 · Cited by 15
Trouw, L. A., Böhringer, S., Daha, N. A., Stahl, E. A., Raychaudhuri, S., Kurreeman, F. A. S., Stoeken‐Rijsbergen, G., Houwing‐Duistermaat, J. J., Huizinga, T. W. J., & Toes, R. E. M. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04482.x · Cited by 13
Wolf, S., Stuck, A. K., Hess, R., Wolf, S., & Enzmann, V. (2009) · Retina · doi:10.1097/iae.0b013e3181a2f40f · Cited by 12
Morris, J. A., Francois, C. G., Olson, P. K., Cotton, B. A., Summar, M. L., Jenkins, J. M., Norris, P. R., Moore, J. H., Williams, A. E., McNew, B. S., et al. (2009) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e31819ea61a · Cited by 12
Saksens, N. T. M., Lechanteur, Y. T. E., Verbakel, S. K., Groenewoud, J. M. M., Daha, M. R., Schick, T., Fauser, S., Boon, C. J. F., Hoyng, C. B., & den Hollander, A. I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0144367 · Cited by 15
“[18,19] Genetic variants in several complement genes have been associated with AMD, including the CFH,[13–15,20] complement factor 3 (C3),[21–25] complement factor B (CFB),[24,26,27] and complement factor I (CFI) genes.”
BackgroundAge-Related Macular Degeneration: Genetics and Biology
Kumaramanickavel, G. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000223 · Cited by 12
Mattes, D., Haas, A., Renner, W., Steinbrugger, I., El‐Shabrawi, Y., Wedrich, A., Werner, C., Schmut, O., & Weger, M. (2009) · PubMed Central · Cited by 12
Bando, H., Shadrach, K. G., Rayborn, M. E., Crabb, J. W., & Hollyfield, J. G. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2006.09.008 · Cited by 12
Epimacular brachytherapy for wet AMD: current perspectives
Casaroli-Marano, R. P., Alforja, S., Giralt, J., & Farah, M. E. (2014) · Clinical ophthalmology · doi:10.2147/opth.s46068 · Cited by 11
Gili, P., Martín, L. L., Martín-Rodrigo, J.-C., Kim-Yeon, N., Modamio-Gardeta, L., Fernández-García, J., Poves, A. B. R., Gómez-Blázquez, E., Pazos, M. R., Pérez‐Fernández, E., et al. (2021) · European Journal of Ophthalmology · doi:10.1177/11206721211002698 · Cited by 11
Depletion of miR-96 Delays, But Does Not Arrest, Photoreceptor Development in Mice
Xiang, L., Zhang, J., Rao, F.-Q., Yang, Q., Zeng, H.-Y., Huang, S., Xie, Z.-X., Lv, J., Lin, D., Chen, X., et al. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.4.24 · Cited by 12
Kato, Y., Oguchi, Y., Omori, T., Kasai, A., Ogasawara, M., Sugano, Y., Itagaki, K., Ojima, A., Ishida, Y., Machida, T., et al. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100167 · Cited by 12
Xu, D., Hou, S., Zhang, J., Jiang, Y., Kijlstra, A., & Yang, P. (2015) · Scientific Reports · doi:10.1038/srep12989 · Cited by 12
Laskowski, J., & Thurman, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-810420-0.00014-6 · Cited by 11
Complement factor B gene polymorphisms and risk of age-related macular degeneration: A meta-analysis
Su, Y., Hu, Z., Pan, T. S., Chen, L., Xie, P., & Liu, Q. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119840245 · Cited by 11
Kim, J.-B., & Lad, E. M. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00822-6 · Cited by 12
Making Biological Sense of Genetic Studies of Age-Related Macular Degeneration
Singh, N., Swaroop, A., & Ratnapriya, R. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-66014-7_8 · Cited by 11
Spencer, K. L., Olson, L. M., Schnetz‐Boutaud, N. C., Gallins, P. J., Wang, G., Scott, W. K., Agarwal, A., Jakobsdóttir, J., Conley, Y. P., Weeks, D. E., et al. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-5112 · Cited by 12
Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
Kaiser, P. K. (2007) · Core evidence · doi:10.2147/ce.s7437 · Cited by 12
“Multiple variations in complement factor B (BF) and component 2 (C2) genes are associated with either increased risk for AMD or providing protective effects against AMD, depending on the variant gene present (Gold et al. 2006); the R32Q single nucleotide polymorphism of BF (H7) and a variant in intron 10 of C2 confer…”
InfluentialZhuang, W., Li, H., Liu, Y., Zhao, J., Ha, S., Wei, X., Bai, X., Li, Z., Han, Y., & Sheng, X. (2014) · Ophthalmic Genetics · doi:10.3109/13816810.2014.921314 · Cited by 12
Therapieansätze bei geographischer Atrophie
Schmitz-Valckenberg, S., Mößner, A., Fleckenstein, M., Wiedemann, P., & Holz, F. G. (2010) · Der Ophthalmologe · doi:10.1007/s00347-010-2160-5 · Cited by 11
Fogerty, J., & Besharse, J. C. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3209-8_45 · Cited by 11
[The role of complement in physiology and pathology].
Klaska, I. P., & Nowak, J. Z. (2007) · PubMed · Cited by 15
A New Era in Psychiatric Genetics?
Insel, T. R., & Lehner, T. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.016 · Cited by 14
Rajesh, A., Gong, J., Chan, K. S., Viniak, R., Droho, S., Kachar, D., Strauss, J. Y., Wang, A. L., & Lavine, J. A. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03398-3 · Cited by 10
“Macrophages express multiple complement components and receptors, which are extensively linked to AMD in genome wide association studies [9, 10, 11, 12].”
Genetic Risk Models in Age-Related Macular Degeneration
Graßmann, F., Heid, I. M., & Weber, B. H. F. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3209-8_37 · Cited by 10
“[9] used a decision tree, which facilitated prediction of AMD disease, but not for computing the AUC.”
BackgroundMethodBaird, P. N., & Chakrabarti, S. (2013) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12235 · Cited by 10
Rare Genetic Variants in Jewish Patients Suffering from Age-Related Macular Degeneration
Shoshany, N., Weiner, C., Safir, M., Lifshitz, A. E., Pokroy, R., Kol, A., Modai, S., Shomron, N., & Pras, E. (2019) · Genes · doi:10.3390/genes10100825 · Cited by 11
Functional Evaluation of AMD-Associated Risk Variants of Complement Factor B
Pilotti, C., Greenwood, J., & Moss, S. E. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.5.19 · Cited by 10
Novel score test to increase power in association test by integrating external controls
Li, Y., & Lee, S. (2020) · Genetic Epidemiology · doi:10.1002/gepi.22370 · Cited by 10
“The AMD‐associated genes revealed by the iECAT‐score were consistent with some well‐known associations such as CFH (J. Maller et al., 2006), C2 (Gold et al., 2006), CFI (Fagerness et al., 2008; Helgason et al., 2013; Seddon et al., 2013; Zhan et al., 2013), RAD51B (Seddon et al., 2014; The…”
BackgroundNeto, J. M., Viturino, M. G. M., Ananina, G., Bajano, F. F., Costa, S. M. D. S., Roque, A. B., Borges, G. F. D. S., Franchi, R., Rim, P. H. H., Medina, F. M. C., et al. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211024543 · Cited by 13
Nusinovici, S., Zhou, L., Wang, X., Tham, Y. C., Wang, X., Wong, T. Y., Chakravarthy, U., & Cheng, C. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100538 · Cited by 10
Chlamydia infection status, genotype, and age-related macular degeneration.
Khandhadia, S., Foster, S., Cree, A. J., Griffiths, H., Osmond, C., Goverdhan, S. V., & Lotery, A. J. (2012) · PubMed Central · Cited by 14
Okur, V., ÇETİN, O., Çetin, E. N., Tepeli, E., Bulğu, Y., & Yıldırım, C. (2014) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12376 · Cited by 11
Acar, İ. E., Willems, E., Kersten, E., Keizer-Garritsen, J. J., Kragt, E., Bakker, B., Galesloot, T. E., Hoyng, C. B., Fauser, S., van Gool, A. J., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121256 · Cited by 10
“In addition, four variants in or near the complement factor B (CFB) and complement component 2 (C2) genes, three variants in or near the complement component 3 (C3) gene, two variants in or near the complement factor I (CFI) gene, one variant in the complement component 9 (C9) gene and one variant near the vitronectin…”
BackgroundOrdóǹez, N. G., & Rosaí, J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06969-4.00024-6 · Cited by 11
Pichi, F., Carrai, P., Srivastava, S. K., Lowder, C. Y., Nucci, P., & Neri, P. (2015) · International Ophthalmology · doi:10.1007/s10792-015-0136-9 · Cited by 10
Qian, D.-G., Kan, M., Weng, X., Huang, Y., Zhou, C., Gen-long, Y., Wang, T., Zhou, D., Zhang, Z., Zhang, D., et al. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.37 · Cited by 12
A review of drug options in age-related macular degeneration therapy and potential new agents
Yeoh, J., Sims, J. L., & Guymer, R. H. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.17.2355 · Cited by 10
“Subsequently, variations in other genes involved in the complement pathway, such as the gene encoding complement factor B, an activator of the alternative complement pathway, has also been shown to be associated with risk of developing AMD [13].”
BackgroundZhang, Y., Watson, B. R., Rattan, A., Lee, T., Chawla, S., Geistlinger, L., Guan, Y., Lord, F. B., Ma, M., Miwa, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66048-5 · Cited by 10
Clinical Characteristics of Neovascular Age‐Related Macular Degeneration without Typical Drusen
Kamao, H., Goto, K., Matsuno, K., Mizukawa, K., Miki, A., & Kiryu, J. (2021) · Journal of Ophthalmology · doi:10.1155/2021/6683532 · Cited by 9
“Mutations/polymorphisms in genes coding for alternative complement pathway regulators (factor H and factor H-related proteins) and complement pathway proteins (complement component C2, C3, and factor B) have been identified as genetic factors in the development of AMD [31–34].”
Larsen, P. P., Delyfer, M., Schweitzer, C., Korobelnik, J., & Delcourt, C. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.01.002 · Cited by 9
Morrison, M. A., Magalhães, T. R., Ramke, J., Smith, S. E., Ennis, S., Simpson, C. L., Portas, L., Murgia, F., Ahn, J., Dardenne, C. N., et al. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00238 · Cited by 10
“…al., 2005; Hughes et al., 2006; Li et al., 2006; Zhang et al., 2008; Sivakumaran et al., 2011); ROBO1 (3p12) (Jun et al., 2011); C2 (6p21 region) (Gold et al., 2006); ARMS2/HTRA1 (10q26) (Dewan et al., 2006; Yang et al., 2006; Deangelis et al., 2008); and RORA (15q22) (Schaumberg et al., 2010;…”
Halili, M. A., Ruiz‐Gómez, G., Le, G. T., Abbenante, G., & Fairlie, D. P. (2009) · Biochemistry · doi:10.1021/bi900679r · Cited by 9
Complement Polymorphisms in Kidney Transplantation: Critical in Graft Rejection?
Michielsen, L. A., van Zuilen, A. D., Muskens, I. S., Verhaar, M. C., & Otten, H. G. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14199 · Cited by 9
“Because of the strong LD between the SNPs on C2 and factor B, it is not completely certain whether the protective effect should be attributed to factor B or C2 (41).”
Ahmad, A., Mandwie, M., Dreismann, A. K., Smyth, C. M., Doyle, H. J., Malik, T. H., Pickering, M. C., Lachmann, P. J., Alexander, I. E., & Logan, G. J. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.022 · Cited by 9
“Dry AMD is a prime target for AP modulation given its association with the hyperactive complotype [6, 8, 11-13].”
Li, F., Li, Y., Li, M., Sun, Y., Bai, Y., Yang, F., Guo, J., Chen, Y., Huang, L., & Li, X. (2014) · Ophthalmic Research · doi:10.1159/000357978 · Cited by 9
Complement Factor H: Using Atomic Resolution Structure to Illuminate Disease Mechanisms
Barlow, P. N., Hageman, G. S., & Lea, S. M. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-78952-1_10 · Cited by 13
“The AMD-CFH discovery was followed by the identification of an association of AMD with three additional complement regulators – Complement Factor B and component 2 (CFB/C2) on chromosome 6p21 (Gold et al. 2006) and C3 on chromosome 19p13 (Maller et al.”
BackgroundSelf-citationMa, W., Paik, D. C., & Barile, G. R. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14352 · Cited by 11
Self-citationTorrini, M., Marchese, C. A., Vanzetti, M., Marini, V., Origone, P., Garrè, C., & Mareni, C. (2007) · Genetic Testing · doi:10.1089/gte.2007.0021 · Cited by 9
“Recent Recent findings suggest that PLEKHA1 / LOC387715 genes on chromosome 10 (Jakobsdottir et al ., 2005) and BF / C2 genes on chromosome 6 (Gold et al ., 2006) are also related to AMD.”
Ho, L., van Leeuwen, R., de Jong, P. T. V. M., Vingerling, J. R., & Klaver, C. C. W. (2012) · Springer eBooks · doi:10.1007/978-3-642-22107-1_1 · Cited by 10
Kenney, M. C., Estrago-Franco, M., Moustafa, M. T., Riazi-Esfahani, M., Sapkal, A. U., Piche-Lopez, R., Patil, A. J., Sharma, A., Falatoonzadeh, P., Chwa, M., et al. (2016) · Journal of Ophthalmic and Vision Research · doi:10.4103/2008-322x.194091 · Cited by 10
“[25] The pathological relevance of the genetic studies is supported by the demonstration that drusen contain complement proteins, including CFH,[25‐28] complement components C3,[29,30] C2, CFB[31,32] C5, Cq1, the membrane attack complex (MAC), and C5b‐9.”
BackgroundChemical Approaches to Modulating Complement-Mediated Diseases
Iyer, A., Xu, W., Reid, R. C., & Fairlie, D. P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00882 · Cited by 9
Annamalai, B., Parsons, N., Brandon, C. S., & Rohrer, B. (2020) · Molecular vision · Cited by 10
Integration and functionality of human iPSC-derived microglia in a chimeric mouse retinal model
Chun, T., Zhou, Q., Huang, X., Ju, Y.-Y., Rao, B., Liu, Z.-C., Jia, Y.-A., Bai, Z., Lin, Q.-Y., Liu, L. L., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03393-8 · Cited by 8
“Genome-wide association analysis has identified several genes associated with the pathogenesis of AMD, including CFH, C2, and C3 [6–8], which are notably expressed in microglia [9].”
Liu, K., Ma, L., Lai, T. Y. Y., Brelen, M. E., Tam, P. O. S., Tham, C. C. Y., Pang, C. P., & Chen, L. J. (2019) · Eye and Vision · doi:10.1186/s40662-019-0161-2 · Cited by 8
Low-frequency inherited complement receptor variants are associated with purpura fulminans
Bendapudi, P. K., Nazeen, S., Ryu, J. H., Söylemez, O., Robbins, A. K., Rouaisnel, B., O'Neil, J. K., Pokhriyal, R., Yang, M., Colling, M. E., et al. (2023) · Blood · doi:10.1182/blood.2023021231 · Cited by 9
Hallam, T. M., Andreadi, A., Sharp, S. J., Brocklebank, V., Gardenal, E., Dreismann, A. K., Arora, R., Dennis, M., Flaxel, C. J., Hall, E., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107452 · Cited by 8
Kamao, H., Mitsui, E., Date, Y., Goto, K., Mizukawa, K., & Miki, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133757 · Cited by 8
“Soft drusen contain various inflammatory components, and mutations/polymorphisms in genes coding for complement pathways have been identified as contributors to the pathogenesis of AMD [22,23].”
BackgroundDry and neovascular “wet” age-related macular degeneration: Upcoming therapies
Yan, A., Hasan, N., & Chhablani, J. K. (2024) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1120_24 · Cited by 9
Quellec, G., Russell, S. R., Seddon, J. M., Reynolds, R. C., Scheetz, T. E., Mahajan, V. B., Stone, E. M., & Abràmoff, M. D. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6793 · Cited by 10
Sheridan, C., Krishna, Y., Williams, R., Mason, S. L., Wong, D., Heimann, H., Kent, D. L., & Grierson, I. (2007) · Expert Review of Ophthalmology · doi:10.1586/17469899.2.3.497 · Cited by 8
Govindaiah, A., Baten, A., Smith, R. T., Balasubramanian, S., & Bhuiyan, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111127 · Cited by 9
“AMD has been associated with many genetic and environmental risk factors and their interactions [4].”
BackgroundSelf-citationGrigsby, D., Klingeborn, M., Kelly, U., Chew, L. A., Asokan, A., Devlin, G. W., Smith, S. M. R., Keyes, L. R., Timmers, A. M., Scaria, A., et al. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.10.25 · Cited by 8
“The tCFH cDNA was designed to encode all 20 of the SCRs in full-length CFH except SCRs 16 and 17 (Fig.”
GENOTYPE–PHENOTYPE ASSOCIATIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Hogg, R. E., McKay, G. J., Hughes, A. E., Muldrew, K. A., & Chakravarthy, U. (2012) · Retina · doi:10.1097/iae.0b013e31824dadf1 · Cited by 10
Complement Activation and Inhibition in Retinal Diseases
Kleinman, M. E., & Ambati, J. (2015) · Developments in ophthalmology · doi:10.1159/000431141 · Cited by 8
Osthoff, M. F., Dean, M. M., Baird, P. N., Richardson, A. J., Daniell, M. D., Guymer, R. H., & Eisen, D. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134107 · Cited by 8
Self-citationVelissari, A., Skalidakis, I., Oliveira, S. C., Koutsandrea, C., Kitsos, G., Petersen, M. B., & Κroupis, C. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0920 · Cited by 8
Havvas, I., Marioli, D. I., Deli, A., Zarkadis, I. K., & Pharmakakis, N. M. (2014) · European Journal of Ophthalmology · doi:10.5301/ejo.5000427 · Cited by 10
Sturgill, G. M., Pauer, G. J. T., Bala, E., Simpson, E., Yaniglos, S. S., Crabb, J. W., Hollyfield, J. G., Lewis, H., Peachey, N. S., & Hagstrom, S. A. (2006) · Ophthalmic Genetics · doi:10.1080/13816810600976871 · Cited by 8
Oldmeadow, C. J., Riveros, C., Holliday, E. G., Scott, R. J., Moscato, P., Wang, J. J., Mitchell, P., Buitendijk, G. H. S., Vingerling, J. R., Klaver, C. C. W., et al. (2011) · Genetic Epidemiology · doi:10.1002/gepi.20622 · Cited by 8
“This prompted further candidate gene association studies of other genes in the complement pathway, leading to the discovery of variants in CFB/C2 [Gold et al., 2006; Maller et al., 2006].”
BackgroundYe, Z., Shuai, P., Zhai, Y., Li, F., Jiang, L., Lü, F., Wen, F., Huang, L., Zhang, D., Liu, X., et al. (2016) · Scientific Reports · doi:10.1038/srep20914 · Cited by 8
Analysis of Macular Drusen and Blood Test Results in 945 Macaca fascicularis
Nishiguchi, K. M., Yokoyama, Y., Fujii, Y., Fujita, K., Tomiyama, Y., Kawasaki, R., Furukawa, T., Ono, F., Shimozawa, N., Togo, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164899 · Cited by 8
Big DNA as a tool to dissect an age-related macular degeneration-associated haplotype
Laurent, J. M., Fu, X., German, S. V., Maurano, M. T., Zhang, K., & Boeke, J. D. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby019 · Cited by 8
“Environmental risk factors are likely only modifiers of existing predisposition to AMD, and indeed we (Zhang) and others have performed genome-wide association studies (GWAS) to demonstrate that development and progression of AMD is strongly tied to a number of loci, such as the complement pathway genes complement fac…”
Background
Metadata
- Authors
- The AMD Genetics Clinical Study Group, Gold, B., Merriam, J. E., Zernant, J., Hancox, L. S., Taiber, A. J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., Barile, G. R., Smith, R. T., Hageman, G. S., Dean, M., & Allikmets, R.
- Affiliations
- National Cancer Institute (US)
- Columbia University (US)
- University of Iowa (US)
- Science Applications International Corporation (United States) (US)
- Corresponding author
- Dean, Michael
- Allikmets, Rando
- ORCID
- Venue
- Nature Genetics
- Published
- 2006-03-05
- Volume
- 38
- Issue
- 4
- Pages
- 458-462
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC2921703
- OpenAlex
- W1997288094
- Cited by
- 1,075
- References
- 31
- Citations by year
- 2026: 17 · 2025: 17 · 2024: 18 · 2023: 17 · 2022: 27 · 2021: 40 · 2020: 33 · 2019: 28 · 2018: 27 · 2017: 31 · 2016: 47 · 2015: 65 · 2014: 74 · 2013: 69 · 2012: 90
- FWCI
- 85.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Eye Institute (EY11515, R01EY013435, EY-13435, R01EY015520, R01EY011515)
- National Cancer Institute (N01-CO-124000)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- age-related macular degeneration, factor B, alternative complement pathway, genetic risk variants, haplotypes, complement factor H, MHC class III, genetic susceptibility
- MeSH terms
- Aged, Aged, 80 and over, Aging, Chromatography, High Pressure Liquid, Complement C2, Haplotypes, Humans, Immunohistochemistry, Macular Degeneration, Molecular Sequence Data, Complement Factor B, Cohort Studies, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.